IKZF2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1403638	0.53	12/20
SCHEMBL1413830	0.51	12/20
SCHEMBL70344	0.49	12/20
SCHEMBL60528	0.47	12/20
SCHEMBL61733	0.47	12/20
SCHEMBL1413488	0.62	11/20
SCHEMBL1413684	0.59	11/20
SCHEMBL1413424	0.57	11/20
SCHEMBL1403759	0.56	11/20
SCHEMBL1413546	0.55	11/20
SCHEMBL1413361	0.55	11/20
SCHEMBL1413631	0.52	11/20
SCHEMBL4450785	0.52	11/20
SCHEMBL70359	0.52	11/20
Hydrochloric Acid (SCHEMBL62435)	0.51	11/20
SCHEMBL1403502	0.51	11/20
SCHEMBL4450744	0.51	11/20
SCHEMBL4461692	0.51	11/20
SCHEMBL1413528	0.49	11/20
SCHEMBL1403535	0.48	11/20

Clinical trials — most relevant to IKZF2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	PHASE3	ACTIVE_NOT_RECRUITING
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients	PHASE3	RECRUITING
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	PHASE1/PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation	PHASE2	UNKNOWN
Decitabine in Treating Patients With Myelofibrosis	PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation	PHASE2	COMPLETED
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)	PHASE1	NOT_YET_RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia	PHASE1	SUSPENDED
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy	nan	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Better Delineation of BCL11B Related Phenotype and Epigenetic Signature.	nan	COMPLETED
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia	nan	COMPLETED
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies	nan	RECRUITING
The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a IKZF2 binder may also engage these)

Protein	Name	Similarity
P81183	—	1.000	P81183 →
IKZF1	DNA-binding protein Ikaros	1.000	landscape →
O13089	—	0.998	O13089 →
O42410	—	0.997	O42410 →
A2VDW9	—	0.996	A2VDW9 →
Q5R9W9	—	0.995	Q5R9W9 →
Q9H5V7	—	0.994	Q9H5V7 →
A4IFJ6	—	0.993	A4IFJ6 →
P25932	—	0.993	P25932 →
O08900	—	0.993	O08900 →
Q03267	—	0.993	Q03267 →
Q5ZLR2	—	0.992	Q5ZLR2 →
Q9JJN2	—	0.992	Q9JJN2 →
A0JPB4	—	0.992	A0JPB4 →
Q8BU00	—	0.992	Q8BU00 →
P57682	—	0.991	P57682 →
Q6NRM0	—	0.991	Q6NRM0 →
IKZF3	Zinc finger protein Aiolos	0.991	landscape →
Q6GNP2	—	0.991	Q6GNP2 →
Q9R0G7	—	0.990	Q9R0G7 →
O60315	—	0.990	O60315 →
P14404	—	0.990	P14404 →
B7ZRU9	—	0.990	B7ZRU9 →
Q6DBW0	—	0.990	Q6DBW0 →
P40645	—	0.990	P40645 →
Q6ZN30	—	0.990	Q6ZN30 →
O73590	—	0.990	O73590 →
Q5RCU4	—	0.989	Q5RCU4 →
Q62661	—	0.989	Q62661 →
P40647	—	0.989	P40647 →